Topiramate

Generic Name
Topiramate
Brand Names
Eprontia, Qsymia, Qudexy, Topamax, Trokendi
Drug Type
Small Molecule
Chemical Formula
C12H21NO8S
CAS Number
97240-79-4
Unique Ingredient Identifier
0H73WJJ391
Background

Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults. Since 2012, the extended-release formulation has been approved in combination with phentermine for chronic weight management therapy in adults.
...

Indication

Topiramate is indicated for the following conditions: 1)Monotherapy for partial onset or primary generalized tonic-clonic seizures for patients 2 years of age and above 2)Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for both adult and pediatric patients above 2 years old 3)Adjunctive therapy for seizures associat...

Associated Conditions
Alcohol Dependency, Epilepsy, Primary Generalized Tonic-Clonic Seizures, Generalized Tonic-Clonic Seizures, Lennox-Gastaut Syndrome, Migraine, Moods Disorders, Partial-Onset Seizures, Seizures, Weight
Associated Therapies
Chronic Weight Management therapy, Weight Reduction

Topiramate Augmentation in Bulimia Nervosa Partial Responders

Phase 4
Withdrawn
Conditions
First Posted Date
2009-10-02
Last Posted Date
2015-07-15
Lead Sponsor
Neuropsychiatric Research Institute, Fargo, North Dakota
Registration Number
NCT00988481
Locations
🇺🇸

Neuropsychiatric Research Institute (NRI), Fargo, North Dakota, United States

A Pharmacokinetic Study of Lithium Before and During Topiramate Dosing in Bipolar Disorder Patients

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-09-29
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
32
Registration Number
NCT00986128

Topiramate Treatment for Patients With Epilepsy and Learning Disability : A Prospective Observational Study

Conditions
Interventions
First Posted Date
2009-08-11
Last Posted Date
2009-08-11
Lead Sponsor
Chinese University of Hong Kong
Target Recruit Count
50
Registration Number
NCT00956696
Locations
🇭🇰

Prince of Wales Hospital, Hong Kong, Hong Kong

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fed Conditions

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-07-15
Last Posted Date
2011-10-10
Lead Sponsor
Torrent Pharmaceuticals Limited
Target Recruit Count
18
Registration Number
NCT00939705
Locations
🇺🇸

Gateway Medical Research, Inc., St, Charles, Missouri, United States

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-07-15
Last Posted Date
2013-07-16
Lead Sponsor
Torrent Pharmaceuticals Limited
Target Recruit Count
26
Registration Number
NCT00939692
Locations
🇺🇸

Gateway Medical Research, Inc., St, Charles, Missouri, United States

Bioequivalence Study of Topiramate Tablets 25mg Under Fed Conditions

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2009-05-15
Last Posted Date
2009-05-15
Lead Sponsor
Ranbaxy Laboratories Limited
Target Recruit Count
18
Registration Number
NCT00902473
Locations
🇨🇦

MDS Pharina Services (Clinical Research Center), Quebec, Canada

Bioequivalence Study of Topiramate Tablets 25mg Under Fasting Conditions

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2009-05-14
Last Posted Date
2009-06-18
Lead Sponsor
Ranbaxy Laboratories Limited
Target Recruit Count
28
Registration Number
NCT00901784
Locations
🇨🇦

MDS Pharina Services (Clinical Research Center), St. Laurent, Québec, Canada

Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism

First Posted Date
2009-03-17
Last Posted Date
2015-04-28
Lead Sponsor
Boston Medical Center
Target Recruit Count
85
Registration Number
NCT00862563
Locations
🇺🇸

Boston University School of Medicine, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath